Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00031
|
|||||
Drug Name |
Ramipril
|
|||||
Synonyms |
(2 S ,3 aS,6 aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name); (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid; (2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic; (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p; (2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]; Acovil; Almirall Brand of Ramipril; Altace; Altace (TN); Astra Brand of Ramipril; AstraZeneca Brand of Ramipril; Aventis Brand of Ramipril; Aventis Pharma Brand of Ramipril; Carasel; Cardace; Delix; HOE 498; HOE498; Hoe-498; Hoechst Brand of Ramipril; Hypren; Hytren; Lostapres; Monarch Brand of Ramipril; N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid; Naprix; Pramace; Pramace (discontinued); Promed Brand of Ramipril; Quark; Ramace; Ramipril (USP/INN); Ramipril [USAN:INN:BAN]; Ramiprilum; Ramiprilum [Latin]; Ramipro, Tritace, Altace, Prilace, Ramipril; Triatec; Tritace; Tritace (TN); Vesdil; Zabien; [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; [2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Congestive heart failure [ICD11: BD10] | Approved | [1] | |||
High blood pressure [ICD11: BA00] | Approved | [1] | ||||
Therapeutic Class |
Antihypertensive Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C23H32N2O5
|
|||||
Canonical SMILES |
CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O
|
|||||
InChI |
InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
|
|||||
InChIKey |
HDACQVRGBOVJII-JBDAPHQKSA-N
|
|||||
CAS Number |
CAS 87333-19-5
|
|||||
Pharmaceutical Properties | Molecular Weight | 416.5 | Topological Polar Surface Area | 95.9 | ||
Heavy Atom Count | 30 | Rotatable Bond Count | 10 | |||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | |||
XLogP |
1.4
|
|||||
PubChem CID | ||||||
PubChem SID |
103339774
, 103984211
, 104170125
, 104179208
, 104253384
, 11364914
, 11367476
, 11370038
, 11372946
, 11374996
, 11378208
, 114149719
, 11491609
, 11493083
, 11495772
, 11528643
, 11533329
, 117664421
, 12012944
, 121362522
, 124658840
, 124757502
, 124799903
, 14904601
, 14929182
, 17184929
, 24724586
, 26612834
, 26719894
, 39384402
, 46386770
, 46506390
, 47721705
, 48244488
, 48416510
, 49664947
, 49681721
, 50122729
, 53787042
, 57362088
, 76755897
, 7847487
, 7980483
, 81093204
, 85279379
, 92308080
, 92308314
, 92309227
, 92712074
, 93166961
|
|||||
ChEBI ID |
ChEBI:8774
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
PEPT2 | Transporter Info | Peptide transporter 2 | Substrate | [2] | ||
References | ||||||
1 | Ramipril was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.